Tianjin Chase Sun Pharmaceutical sees profit fall despite revenue rise in H1 2025

Tianjin Chase Sun Pharmaceutical reported a net profit of 78,630,019.31 yuan for the first half of 2025, marking a 46.95% decrease year-over-year, despite a 6.72% increase in operating revenue to 2,794,968,270.19 yuan. The company allocated 37,083,154.76 yuan for asset impairment provisions, primarily due to inventory depreciation losses.

The company engaged in significant inter-company fund transactions, including 72,655.42 yuan with Zhengkang Medical Technology Co., Ltd. and 22,500.00 yuan with Hubei Yinuorui Bio-Pharmaceutical Co., Ltd. These transactions, classified as non-operating related party fund movements, are stated to support daily production and operation.

Furthermore, Tianjin Chase Sun Pharmaceutical secured a 210,000.00 yuan credit line from various financial institutions for 2025-2026 and committed to provide guarantees not exceeding 400,000.00 yuan for its subsidiaries and sub-subsidiaries within its consolidated financial statement scope. The company's board and supervisory board meetings approved these financial arrangements.